Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00129181
Status:
COMPLETED
Last Update Posted:
2009-08-28
First Post:
2005-08-09
Brief Title:
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinsons Disease
Sponsor:
Institute for Neurodegenerative Disorders
Organization:
Institute for Neurodegenerative Disorders
Study Overview
Official Title:
A Single-blinded Assessment of the Short-term Effects of Cabergoline vs CarbidopaLevodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-4-iodophenyl tropane 123Iß-CIT uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo
Detailed Description:
This is a multi-center open-label study of short-term treatment with levodopa or cabergoline on striatal DATscan uptake in early Parkinsons disease Approximately 120 Parkinsons disease subjects will be randomized to receive either carbidopalevodopa cabergoline or no treatment during a twelve week period Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks After twelve weeks carbidopalevodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks 20 weeks after baseline
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None